Use to monitor complement blockage in patients treated with C5 inhibitor drugs.
C5 INH PAN
Quantitative Turbidimetric/Quantitative Radial Immunodiffusion
New York DOH Approval Status
This test is New York DOH approved.
Separate serum from cells ASAP or within 2 hours of collection. Transfer 2.0 mL serum to an ARUP standard transport tube and freeze immediately. (Min: 2.0 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Specimens received refrigerated, ambient, lipemic specimens, or grossly hemolyzed specimens. Serum separator tubes. Specimens collected using calcium-binding anticoagulants (i.e., EDTA, ACD).
Refer to individual components.
|Complement Activity, Total Turbidimetric||38.7-89.9 U/mL|
|Complement Component 5||7-20 mg/dL|
|Complement Activity, Alternative Pathway||59 percent normal or greater|
|Complement C5, Functional||23.0 U/mL or greater|
|Complement Activity, Total Turbidimetric||Low: 38.6 U/mL or less
Normal: 38.7-89.9 U/mL
High: 90.0 U/mL or greater
|Complement C5, Functional||Low: 22.9 U/mL or less
Low-Normal: 23.0-28.3 U/mL
Normal: 28.4 U/mL or greater
|Complement Activity, Alternative Pathway||This test is intended for screening of functional activity of the alternative pathway of the complement system. Abnormal test results can be due to hereditary absence or acquired functional defect in the activity of any of the individual components of the alternative pathway.|
|C5 Inhibitors Drug Monitoring Pan Interp||Patients treated with C5 inhibitors may show decreased/absent activity in total complement functional assay (CH50), alternative pathway functional assay (AH50), and C5 functional assay with normal or elevated C5 protein concentrations. Normal CH50, AH50, or C5 functional activity with normal or elevated C5 protein concentrations indicate inadequate complement blockage. Serial measurements are recommended when monitoring treatment efficacy. Decreases in both C5 concentration and C5 functional activity suggests a secondary consumption process or C5 deficiency. Repeat testing using a new specimen is suggested if in vitro complement activation and consumption of components due to conditions of collection, transport, and/or handling is suspected.|
Date of Change
Test Name Change
Other Interface Change
86160; 86161 x2; 86162
|Component Test Code*||Component Chart Name||LOINC|
|0050156||Complement Component 5||4505-4|
|2005374||Complement Activity, Alternative Pathway||74520-8|
|3002576||Complement Activity, Total Turbidimetric||4532-8|
|3005962||Complement C5, Functional||60472-8|
|3006097||C5 Inhibitors Drug Monitoring Pan Interp|
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
- C5 inhibitor
- CH50 total
- Complement blocking
- Complement C5
- Complement C5 functional
- Complement monitoring
C5 Inhibitors Drug Monitoring Panel